Long COVID affects an estimated 65 million people worldwide and can damage the brain, heart, blood vessels, and immune system ...
SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors. Its ...
GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...
GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback